Among the drugs currently being tested as adjuncts to insulin therapy in randomized clinical trials (RCTs), sodium glucose co-transport-2 (SGLT2) inhibitors appear promising because they are unique and independent of the mechanism of action of insulin.[4] Overall, SGLT2 inhibitors significantly improve major cardiometabolic parameters (hemoglobin A1c, fasting glucose, blood pressure, lipid distribution, body weight) and are expected to be successful in cardiovascular disease and diabetic kidney disease. This evidence concerns the gene SLC5A2 and diabetic kidney disease.